Vimarsana
Biggest News Aggregation in the World

David Kerstein News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from David Kerstein. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In David Kerstein Today - Breaking & Trending Today

WWOZ Announces New Home Atop Jax Brewery in the Historic French Quarter - Vimarsana News

WWOZ Announces New Home Atop Jax Brewery in the Historic French Quarter

WWOZ is thrilled to announce that our beloved station is relocating and will occupy the entire top (fifth) floor of The Jax Brewery Millhouse building located at 600 Decatur Street.

Source: wwoz.org
Theseus Pharmaceuticals Reports Initial Dose Escalation Data from Ongoing Phase 1/2 Trial of THE-630 in Patients with Advanced GIST - Vimarsana News

Theseus Pharmaceuticals Reports Initial Dose Escalation Data from Ongoing Phase 1/2 Trial of THE-630 in Patients with Advanced GIST

-- THE-630 demonstrates encouraging safety profile through Cohort 6 , supportive of continued dose escalation -- -- Dose-dependent reductions observed in ctDNA KIT-mutant allele fractions for both... | May 25, 2023

Theseus Pharmaceuticals Reports Initial Dose Escalation Data from Ongoing Phase 1/2 Trial of THE-630 in Patients with Advanced GIST - Vimarsana News

Theseus Pharmaceuticals Reports Initial Dose Escalation Data from Ongoing Phase 1/2 Trial of THE-630 in Patients with Advanced GIST

-- THE-630 demonstrates encouraging safety profile through Cohort 6 (18 mg), supportive of continued dose escalation -- -- Dose-dependent reductions observed...

Theseus Pharmaceuticals Receives U.S. FDA Orphan Drug Designation for THE-630 for the Treatment of Advanced Gastrointestinal Stromal Tumors (GIST) - Vimarsana News

Theseus Pharmaceuticals Receives U.S. FDA Orphan Drug Designation for THE-630 for the Treatment of Advanced Gastrointestinal Stromal Tumors (GIST)

/PRNewswire/ -- Theseus Pharmaceuticals, Inc. (Theseus) (NASDAQ: THRX), a clinical-stage biopharmaceutical company focused on improving the lives of cancer...

Theseus Pharmaceuticals Receives U.S. FDA Orphan Drug Designation for THE-630 for the Treatment of Advanced Gastrointestinal Stromal Tumors (GIST) - Vimarsana News

Theseus Pharmaceuticals Receives U.S. FDA Orphan Drug Designation for THE-630 for the Treatment of Advanced Gastrointestinal Stromal Tumors (GIST)

/PRNewswire/ -- Theseus Pharmaceuticals, Inc. (Theseus) (NASDAQ: THRX), a clinical-stage biopharmaceutical company focused on improving the lives of cancer...